HK1257844A1 - 藥物化合物的嘌呤和氮雜嘌呤衍生物 - Google Patents
藥物化合物的嘌呤和氮雜嘌呤衍生物Info
- Publication number
- HK1257844A1 HK1257844A1 HK19100201.4A HK19100201A HK1257844A1 HK 1257844 A1 HK1257844 A1 HK 1257844A1 HK 19100201 A HK19100201 A HK 19100201A HK 1257844 A1 HK1257844 A1 HK 1257844A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- purine
- pharmaceutical compounds
- deazapurine derivatives
- deazapurine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0608179A GB0608179D0 (en) | 2006-04-25 | 2006-04-25 | Pharmaceutical compounds |
GB0608176A GB0608176D0 (en) | 2006-04-25 | 2006-04-25 | Pharmaceutical Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257844A1 true HK1257844A1 (zh) | 2019-11-01 |
Family
ID=38255445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100201.4A HK1257844A1 (zh) | 2006-04-25 | 2009-08-20 | 藥物化合物的嘌呤和氮雜嘌呤衍生物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8796293B2 (zh) |
EP (3) | EP3719018A1 (zh) |
JP (1) | JP5606734B2 (zh) |
DK (1) | DK3421471T3 (zh) |
ES (1) | ES2878130T3 (zh) |
HK (1) | HK1257844A1 (zh) |
WO (1) | WO2007125321A2 (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
ES2558517T3 (es) * | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
US7851484B2 (en) | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
SI2201012T1 (sl) | 2007-10-11 | 2014-10-30 | Astrazeneca Ab | Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B |
AU2008331733A1 (en) * | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta |
CN101959887B (zh) | 2008-01-08 | 2013-07-31 | 阵列生物制药公司 | 作为激酶抑制剂的吡咯并吡啶 |
ES2392014T3 (es) | 2008-01-09 | 2012-12-03 | Array Biopharma, Inc. | Pirazolopiridinas como inhibidores de la cinasa |
AU2009239500B2 (en) | 2008-04-21 | 2014-01-30 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
AU2013218743B2 (en) * | 2008-05-13 | 2016-04-28 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
MX2012004780A (es) | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
RU2565034C2 (ru) * | 2010-02-03 | 2015-10-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Идентификация мутации lkb1 в качестве прогностического биомаркера чувствительности к ингибиторам tor-киназы |
WO2012080735A1 (en) | 2010-12-16 | 2012-06-21 | Convergence Pharmaceuticals Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
DK2694056T3 (da) | 2011-04-01 | 2020-01-02 | Astrazeneca Ab | Terapeutisk behandling |
EA028060B1 (ru) | 2011-07-13 | 2017-10-31 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
ES2646759T3 (es) * | 2011-09-12 | 2017-12-15 | Merck Patent Gmbh | Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
MY175800A (en) | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
RU2619465C2 (ru) * | 2012-10-26 | 2017-05-16 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
WO2014086453A1 (en) * | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
TWI654979B (zh) | 2013-04-17 | 2019-04-01 | 美商標誌製藥公司 | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
TWI656875B (zh) | 2013-04-17 | 2019-04-21 | 美商標誌製藥公司 | 藉二氫吡并吡治療癌症 |
KR102271344B1 (ko) | 2013-04-17 | 2021-07-01 | 시그날 파마소티칼 엘엘씨 | 디하이드로피라지노-피라진을 사용한 암의 치료 |
KR102221005B1 (ko) | 2013-04-17 | 2021-02-26 | 시그날 파마소티칼 엘엘씨 | 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법 |
US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
WO2014172423A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
JP2018507236A (ja) * | 2015-03-04 | 2018-03-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | トリアゾロピリジン化合物及びその使用法 |
SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
WO2021143680A1 (zh) | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
WO2021194607A1 (en) * | 2020-03-25 | 2021-09-30 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat frontotemporal dementia |
WO2023183394A1 (en) * | 2022-03-24 | 2023-09-28 | Curasen Therapeutics, Inc. | Alpha 1a-adrenergic receptor agonists and methods of use |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297170A (zh) | 1963-04-04 | 1900-01-01 | ||
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
IT1252567B (it) | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
TR200000333T2 (tr) | 1997-08-05 | 2000-05-22 | Pfizer Products Inc. | Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler. |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
ID27600A (id) | 1998-06-02 | 2001-04-12 | Osi Pharm Inc | KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA |
CA2333770A1 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
ID26698A (id) | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
EP1244672B1 (en) | 1999-12-21 | 2005-07-20 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
CN1308324C (zh) | 2000-08-31 | 2007-04-04 | 弗·哈夫曼-拉罗切有限公司 | 作为α-1肾上腺素能拮抗剂的喹唑啉衍生物 |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
HUP0400692A3 (en) | 2000-12-01 | 2007-09-28 | Osi Pharmaceuticals | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them |
US6680324B2 (en) * | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
CN100503608C (zh) | 2002-01-07 | 2009-06-24 | 卫材R&D管理株式会社 | 脱氮嘌呤及其用途 |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
TW200410688A (en) * | 2002-06-26 | 2004-07-01 | Ono Pharmaceutical Co | Therapeutics for diseases from vasoconstriction or vasodilatation |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
EP1567495A4 (en) | 2002-11-08 | 2007-10-31 | Harvard College | SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS |
RU2328498C9 (ru) | 2002-12-04 | 2008-12-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединения с конденсированным 1,3-дигидроимидазольным циклом |
EP1444982A1 (de) * | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
SE0300457D0 (sv) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
CN1720246A (zh) | 2003-04-21 | 2006-01-11 | 捷克共和国乌斯塔夫化学与生物化学研究院 | (嘌呤-6-基)氨基酸及其制备方法 |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス, インコーポレイテッド | c−Kit調節因子および使用方法 |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
CN1882347A (zh) | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
US7511159B2 (en) * | 2003-12-25 | 2009-03-31 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
FR2880540B1 (fr) * | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
EP1910358A2 (en) | 2005-07-14 | 2008-04-16 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
WO2007125325A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
EP2013206A1 (en) | 2006-04-25 | 2009-01-14 | Astex Therapeutics Limited | Pharmaceutical compounds |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
SI2201012T1 (sl) | 2007-10-11 | 2014-10-30 | Astrazeneca Ab | Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B |
-
2007
- 2007-04-25 DK DK18182786.6T patent/DK3421471T3/da active
- 2007-04-25 JP JP2009507156A patent/JP5606734B2/ja active Active
- 2007-04-25 WO PCT/GB2007/001518 patent/WO2007125321A2/en active Application Filing
- 2007-04-25 EP EP19216213.9A patent/EP3719018A1/en active Pending
- 2007-04-25 EP EP07732555A patent/EP2043655A2/en not_active Withdrawn
- 2007-04-25 ES ES18182786T patent/ES2878130T3/es active Active
- 2007-04-25 EP EP18182786.6A patent/EP3421471B1/en active Active
- 2007-04-25 US US12/298,462 patent/US8796293B2/en active Active
-
2009
- 2009-08-20 HK HK19100201.4A patent/HK1257844A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20100022564A1 (en) | 2010-01-28 |
EP3719018A1 (en) | 2020-10-07 |
JP5606734B2 (ja) | 2014-10-15 |
EP3421471A1 (en) | 2019-01-02 |
DK3421471T3 (da) | 2021-06-14 |
WO2007125321A3 (en) | 2007-12-27 |
US8796293B2 (en) | 2014-08-05 |
WO2007125321A2 (en) | 2007-11-08 |
EP2043655A2 (en) | 2009-04-08 |
ES2878130T3 (es) | 2021-11-18 |
JP2009534455A (ja) | 2009-09-24 |
EP3421471B1 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257844A1 (zh) | 藥物化合物的嘌呤和氮雜嘌呤衍生物 | |
IL202622A (en) | Purin derivatives and pharmaceuticals containing them | |
IL194460A0 (en) | Deazapurine derivatives and pharmaceutical compositions containing the same | |
IL191907A0 (en) | Azepinoindole derivatives as pharmaceutical agents | |
IL193240A0 (en) | Dihydrodiazepine derivatives and pharmaceutical compositions containing the same | |
GB2450753B (en) | New Pharmaceutical formulation | |
IL191902A0 (en) | Azaindole derivatives and pharmaceutical compositions containing the same | |
IL196601A0 (en) | Pyrimidine derivatives and pharmaceutical compositions containing the same | |
ZA200808530B (en) | Pharmaceutical composition for external use | |
ZA200809002B (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
IL196033A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
ZA200808531B (en) | Pharmaceutical composition for external use | |
IL194546A0 (en) | Arylaminopyridine derivatives and pharmaceutical compositions containing them | |
IL191531A0 (en) | Orally absorbed pharmaceutical formulation | |
HK1125295A1 (zh) | 基於微片的藥物製劑 | |
AP2008004671A0 (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
GB0614586D0 (en) | Pharmaceutical Formulation | |
IL206594A (en) | The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations | |
IL193211A (en) | Derivatives of Indzol-Troaril and pharmaceutical preparations containing them | |
EP2193795A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST | |
ZA200702234B (en) | Preparation of ester of purine derivatives | |
GB0719248D0 (en) | Compounds and methods for pharmaceutical use | |
EP2124959A4 (en) | PHARMACEUTICAL COMPOSITION | |
IL198160A0 (en) | Pharmaceutical formulations | |
GB0608176D0 (en) | Pharmaceutical Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: GARRETT, MICHELLE, DAWN Effective date: 20211130 |